Your browser doesn't support javascript.
Tocilizumab reduces COVID-19 mortality and pathology in a dose and timing-dependent fashion: a multi-centric study.
Durán-Méndez, Alejandro; Aguilar-Arroyo, Alma Delia; Vivanco-Gómez, Emiliano; Nieto-Ortega, Eduardo; Pérez-Ortega, Daniela; Jiménez-Pérez, Cristian; Hernández-Skewes, Karla Y; Montiel-Bravo, Guillermo; Roque-Reyes, Oscar J; Romero-Lechuga, Fernanda; Medina-Santos, Diana; Oriana-Román, Perla; Flores-Hernández, Jorge Rafael; Méndez-Coca, Juan Daniel; Montaño-Olmos, Daniela; Farfán-Lazos, Karla Cecilia; Tobón-Cubillos, Miranda; Viveros-Hernández, América; Sevilla-Castillo, Fernando; Hernández-Romero, Ángel Raúl; Ortega-Rodríguez, Shannat; Jardínez-Vera, Aldo Christiaan; Solís-González, María Antonieta; de la Medina, Antonio Ramos; Pérez-Maldonado, Laura Martínez; Lagunes-Lara, Elizabeth; Cova-Bonilla, Miguel; Peón, Alberto N.
  • Durán-Méndez A; Laboratorio Santiago Ramón y Cajal, Sociedad Española de Beneficencia, Av. Juárez #908, Col. La Villita, CP42060, Pachuca, Hidalgo, Mexico.
  • Aguilar-Arroyo AD; Área Académica de Medicina, Universidad Autónoma del Estado de Hidalgo, Pachuca, Mexico.
  • Vivanco-Gómez E; Laboratorio Santiago Ramón y Cajal, Sociedad Española de Beneficencia, Av. Juárez #908, Col. La Villita, CP42060, Pachuca, Hidalgo, Mexico.
  • Nieto-Ortega E; Escuela Superior de Apan, Universidad Autónoma del Estado de Hidalgo, Carretera Apan-Calpulalpan s/n, Colonia, 43920, Chimalpa Tlalayote, Hgo, Mexico.
  • Pérez-Ortega D; Laboratorio Santiago Ramón y Cajal, Sociedad Española de Beneficencia, Av. Juárez #908, Col. La Villita, CP42060, Pachuca, Hidalgo, Mexico.
  • Jiménez-Pérez C; Área Académica de Medicina, Universidad Autónoma del Estado de Hidalgo, Pachuca, Mexico.
  • Hernández-Skewes KY; Laboratorio Santiago Ramón y Cajal, Sociedad Española de Beneficencia, Av. Juárez #908, Col. La Villita, CP42060, Pachuca, Hidalgo, Mexico.
  • Montiel-Bravo G; Área Académica de Medicina, Universidad Autónoma del Estado de Hidalgo, Pachuca, Mexico.
  • Roque-Reyes OJ; Laboratorio Santiago Ramón y Cajal, Sociedad Española de Beneficencia, Av. Juárez #908, Col. La Villita, CP42060, Pachuca, Hidalgo, Mexico.
  • Romero-Lechuga F; Área Académica de Medicina, Universidad Autónoma del Estado de Hidalgo, Pachuca, Mexico.
  • Medina-Santos D; Laboratorio Santiago Ramón y Cajal, Sociedad Española de Beneficencia, Av. Juárez #908, Col. La Villita, CP42060, Pachuca, Hidalgo, Mexico.
  • Oriana-Román P; Escuela Superior de Apan, Universidad Autónoma del Estado de Hidalgo, Carretera Apan-Calpulalpan s/n, Colonia, 43920, Chimalpa Tlalayote, Hgo, Mexico.
  • Flores-Hernández JR; Laboratorio Santiago Ramón y Cajal, Sociedad Española de Beneficencia, Av. Juárez #908, Col. La Villita, CP42060, Pachuca, Hidalgo, Mexico.
  • Méndez-Coca JD; Área Académica de Medicina, Universidad Autónoma del Estado de Hidalgo, Pachuca, Mexico.
  • Montaño-Olmos D; Laboratorio Santiago Ramón y Cajal, Sociedad Española de Beneficencia, Av. Juárez #908, Col. La Villita, CP42060, Pachuca, Hidalgo, Mexico.
  • Farfán-Lazos KC; Área Académica de Medicina, Universidad Autónoma del Estado de Hidalgo, Pachuca, Mexico.
  • Tobón-Cubillos M; Laboratorio Santiago Ramón y Cajal, Sociedad Española de Beneficencia, Av. Juárez #908, Col. La Villita, CP42060, Pachuca, Hidalgo, Mexico.
  • Viveros-Hernández A; Área Académica de Medicina, Universidad Autónoma del Estado de Hidalgo, Pachuca, Mexico.
  • Sevilla-Castillo F; Laboratorio Santiago Ramón y Cajal, Sociedad Española de Beneficencia, Av. Juárez #908, Col. La Villita, CP42060, Pachuca, Hidalgo, Mexico.
  • Hernández-Romero ÁR; Área Académica de Medicina, Universidad Autónoma del Estado de Hidalgo, Pachuca, Mexico.
  • Ortega-Rodríguez S; Laboratorio Santiago Ramón y Cajal, Sociedad Española de Beneficencia, Av. Juárez #908, Col. La Villita, CP42060, Pachuca, Hidalgo, Mexico.
  • Jardínez-Vera AC; Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico, Mexico.
  • Solís-González MA; Laboratorio Santiago Ramón y Cajal, Sociedad Española de Beneficencia, Av. Juárez #908, Col. La Villita, CP42060, Pachuca, Hidalgo, Mexico.
  • de la Medina AR; Área Académica de Medicina, Universidad Autónoma del Estado de Hidalgo, Pachuca, Mexico.
  • Pérez-Maldonado LM; Laboratorio Santiago Ramón y Cajal, Sociedad Española de Beneficencia, Av. Juárez #908, Col. La Villita, CP42060, Pachuca, Hidalgo, Mexico.
  • Lagunes-Lara E; Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Mexico, Mexico.
  • Cova-Bonilla M; Laboratorio Santiago Ramón y Cajal, Sociedad Española de Beneficencia, Av. Juárez #908, Col. La Villita, CP42060, Pachuca, Hidalgo, Mexico.
  • Peón AN; Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Mexico, Mexico.
Sci Rep ; 11(1): 19728, 2021 10 05.
Article in English | MEDLINE | ID: covidwho-1454814
ABSTRACT
Life-threatening COVID-19 is associated with strong inflammation, where an IL-6-driven cytokine storm appears to be a cornerstone for enhanced pathology. Nonetheless, the specific inhibition of such pathway has shown mixed outcomes. This could be due to variations in the dose of tocilizumab used, the stage in which the drug is administered or the severity of disease presentation. Thus, we performed a retrospective multicentric study in 140 patients with moderate to critical COVID-19, 79 of which received tocilizumab in variable standard doses (< 400 mg, 400-800 mg or > 800 mg), either at the viral (1-7 days post-symptom onset), early inflammatory (8-15) or late inflammatory (16 or more) stages, and compared it with standard treated patients. Mortality, reduced respiratory support requirements and pathology markers were measured. Tocilizumab significantly reduced the respiratory support requirements (OR 2.71, CI 1.37-4.85 at 95%) and inflammatory markers (OR 4.82, CI 1.4-15.8) of all patients, but mortality was only reduced (4.1% vs 25.7%, p = 0.03) when the drug was administered at the early inflammatory stage and in doses ranging 400-800 mg in severely-ill patients. Despite the apparent inability of Tocilizumab to prevent the progression of COVID-19 into a critical presentation, severely-ill patients may be benefited by its use in the early inflammatory stage and moderate doses.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / COVID-19 Drug Treatment Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-99291-z

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / COVID-19 Drug Treatment Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: Sci Rep Year: 2021 Document Type: Article Affiliation country: S41598-021-99291-z